Therefore, targeting EZH2 is considered a prominent approach to treating lymphoma, and tazemetostat, which specifically targets the EZH2 SET domain, has been approved for patients with follicular lymphoma and epithelioid sarcoma [63, 64]. This evidence concerns the gene EZH2 and epithelioid sarcoma.